InsiderTrades.com logo

RNTX Insider Trading

Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $550,563.12
Insider Selling (Last 12 Months): $0.00

Rein Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Rein Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rein Therapeutics Share Price & Price History

Current Price: $1.39
Price Change: ▲ Price Increase of +0.01 (0.72%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for RNTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Rein Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2025Voss Capital, LpMajor ShareholderBuy104,183$1.22$127,103.26926,441View SEC Filing Icon  
10/28/2025Voss Capital, LpMajor ShareholderBuy178,392$1.39$247,964.88500,000View SEC Filing Icon  
10/27/2025Voss Capital, LpMajor ShareholderBuy97,482$1.37$133,550.34822,258View SEC Filing Icon  
10/24/2025Voss Capital, LpMajor ShareholderBuy30,176$1.39$41,944.64729,616View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Rein Therapeutics (NASDAQ:RNTX)

90.89% of Rein Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RNTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Rein Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/20/2025Voss Capital LP2,666,532$3.05M0.1%+86.0%10.143%Search for SEC Filing on Google Icon
11/17/2025Susquehanna International Group LLP30,860$35K0.0%N/A0.132%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC28,201$32K0.0%-41.2%0.121%Search for SEC Filing on Google Icon
11/14/2025Prosight Management LP567,898$0.65M0.2%+32.7%2.436%Search for SEC Filing on Google Icon
11/7/2025Vanguard Group Inc.1,168,407$1.34M0.0%+32.2%5.014%Search for SEC Filing on Google Icon
11/3/2025Gagnon Securities LLC228,692$0.26M0.1%+218.8%0.981%Search for SEC Filing on Google Icon
10/16/2025Gleason Group Inc.22,389$26K0.0%N/A0.096%Search for SEC Filing on Google Icon
8/14/2025Cable Car Capital LP420,000$0.59M0.2%N/A1.822%Search for SEC Filing on Google Icon
8/14/2025Voss Capital LP1,433,686$2.01M0.1%N/A6.221%Search for SEC Filing on Google Icon
8/13/2025Northwestern Mutual Wealth Management Co.48,662$68K0.0%N/A0.211%Search for SEC Filing on Google Icon
8/12/2025BIOS Capital Management LP1,690,751$2.37M3.3%N/A7.335%Search for SEC Filing on Google Icon
8/12/2025Meridian Wealth Advisors LLC28,486$40K0.0%N/A0.124%Search for SEC Filing on Google Icon
8/11/2025Senvest Management LLC230,895$0.32M0.0%N/A1.002%Search for SEC Filing on Google Icon
8/8/2025Geode Capital Management LLC245,455$0.34M0.0%N/A1.065%Search for SEC Filing on Google Icon
8/5/2025Sigma Planning Corp276,777$0.39M0.0%N/A1.201%Search for SEC Filing on Google Icon
7/31/2025University of Texas Texas AM Investment Management Co.511,610$0.72M0.1%N/A2.310%Search for SEC Filing on Google Icon
7/30/2025Exencial Wealth Advisors LLC30,528$43K0.0%N/A0.138%Search for SEC Filing on Google Icon
7/29/2025Chicago Partners Investment Group LLC41,242$64K0.0%N/A0.186%Search for SEC Filing on Google Icon
7/24/2025Blair William & Co. IL23,622$33K0.0%N/A0.107%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Rein Therapeutics logo
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Read More on Rein Therapeutics

Today's Range

Now: $1.39
Low: $1.35
High: $1.43

50 Day Range

MA: $1.38
Low: $1.15
High: $1.75

52 Week Range

Now: $1.39
Low: $1.04
High: $3.50

Volume

190,699 shs

Average Volume

239,572 shs

Market Capitalization

$36.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Who are the company insiders with the largest holdings of Rein Therapeutics?

Rein Therapeutics' top insider investors include:
  1. Voss Capital, Lp (Major Shareholder)
Learn More about top insider investors at Rein Therapeutics.

Who are the major institutional investors of Rein Therapeutics?

Rein Therapeutics' top institutional investors include:
  1. Voss Capital LP — 10.14%
  2. Vanguard Group Inc. — 5.01%
  3. Prosight Management LP — 2.44%
  4. Gagnon Securities LLC — 0.98%
  5. Susquehanna International Group LLP — 0.13%
  6. Citadel Advisors LLC — 0.12%
Learn More about top institutional investors of Rein Therapeutics stock.

Which institutional investors are selling Rein Therapeutics stock?

In the previous quarter, RNTX stock was sold by these institutional investors:
  1. Citadel Advisors LLC

Which institutional investors are buying Rein Therapeutics stock?

In the previous quarter, RNTX stock was purchased by institutional investors including:
  1. Voss Capital LP
  2. Vanguard Group Inc.
  3. Gagnon Securities LLC
  4. Prosight Management LP
  5. Susquehanna International Group LLP
  6. Gleason Group Inc.